Prodia Diagnostic Line Prepares IPO on the Stock Exchange

JAKARTA — Prodia Diagnostic Line is preparing an IPO on the Stock Exchange through an initial public offering on the Indonesia Stock Exchange under the ticker PRDL. The Prodia Group subsidiary plans to offer up to 552.9 million shares, equal to 30 percent of its issued and fully paid-up capital after the offering.

The preliminary offering price is set between Rp100 and Rp120 per share. From that range, the company’s fundraising scale is already visible. It is not small. Enough to catch the eye of retail investors, especially since the Prodia name is already familiar in Indonesia’s healthcare services market.

The preliminary prospectus, cited on Sunday, June 21, 2026, also includes an Employee Stock Allocation program, or ESA. The company plans to set aside up to 36.6 million shares. That amount is equal to 7 percent of the shares offered to the public in the IPO.

For everyday readers, news like this matters not just because a new company is heading to the market. An IPO reveals how ambitious a business is, how wide its reach may be, and how confident management feels about the capital market. In Proline’s case, the public can gauge whether the medical equipment business still has enough room to grow in investors’ eyes.

Who Proline is and what it is offering investors

PT Prodia Diagnostic Line Tbk., or Proline, operates as a medical device manufacturer. The company sits under the Prodia Group, a business group long associated with diagnostics and healthcare services. With its planned listing on the IDX, Proline will use the stock code PRDL.

This move puts Proline on the radar of investors looking at the healthcare sector, especially medical devices, which are often seen as relatively stable in demand. Medical equipment products are not tied to just one season. Demand keeps coming. From laboratories and healthcare facilities to distribution networks, this market moves differently from the consumer sector.

But an IPO also demands more transparency. The company must disclose more information to the public, from capital structure and use of proceeds to business plans. At this point, investors are not just buying shares. They are buying a growth story, governance, and execution discipline.

IPO figures on the stock exchange to watch

The preliminary prospectus states that up to 552.9 million shares will be offered, or 30 percent of the issued and fully paid-up capital after the IPO. The initial price range is Rp100 to Rp120 per share. From that, the gross fundraising value could range from around Rp55.29 billion to Rp66.35 billion, using the lower and upper ends of the offer.

Those numbers are not final because the offering price may still change during the bookbuilding period. Even so, the initial range sends an important signal. The company appears to be choosing a relatively measured valuation so the market has room to absorb the new shares. This is a common strategy for issuers that want to keep investor interest strong from the start.

The ESA program is also notable. Up to 36.6 million shares are reserved for employees. Such a scheme is usually used to align staff interests with company performance. Employees who own shares tend to stay closer to business targets. They feel the ups and downs of the stock price, not just the monthly payroll.

Why this IPO on the Stock Exchange matters for investors

In the capital market, an IPO from a healthcare company is usually viewed from two angles. First, growth potential. Second, demand stability. Medical device products have an appealing profile because they are used in recurring healthcare services. That is why some investors see the sector as having decent resilience.

Still, investors need to look deeper. How much of sales come from the domestic market? How dependent is the company on raw materials? How high are production costs? And most important, how will IPO proceeds be used? Without those details, buying shares turns into little more than betting on a big name.

“The public usually looks at the reputation of a big business group, but what matters more is the business model, margins, and how the funds will be used,” said a capital market analyst who regularly covers healthcare issuers. “If those three things are clear, investors have a healthier basis for judging it.”

That view fits here. The Prodia name does carry weight. But the stock market does not stop at reputation. The exchange demands numbers. Investors want to know whether the IPO money will go into expansion, working capital, or other needs that can support future profits.

Why the market will pay attention

Proline’s arrival on the bourse is also interesting because the medical device sector sits at the intersection of basic need and business opportunity. When healthcare services grow, demand for supporting equipment also rises. When medical facilities expand services, manufacturers of medical devices usually benefit as well.

For retail investors, a new issuer also means more diversification options. A portfolio does not have to be filled only with banks, miners, or consumer stocks. Healthcare shares can serve as a complement, though they still need to be bought carefully. A low price does not guarantee safety. A high price does not automatically mean the stock is expensive if the business outlook is strong.

One thing should not be missed: every IPO carries two stories at once. A growth story. And a discipline story. The market will test both once PRDL begins trading. From there, the public can see whether early interest turns into longer-term market confidence.

For now, the data released is still at the initial stage. But it is enough to show Proline’s direction. The company is entering the exchange with a 30 percent share offering, a Rp100-Rp120 price range, and an employee allocation equal to 7 percent of the shares offered. That final figure may look small on paper, but it often sends a strong early signal: management wants insiders to share the same fate as the company itself.

Brief summary: Prodia Diagnostic Line is preparing an IPO on the Stock Exchange under the ticker PRDL. The company plans to offer up to 552.9 million shares at Rp100-Rp120 each. An ESA program of up to 36.6 million shares is also being prepared.

Quick FAQ: What is the stock code? PRDL. How much is being offered to the public? 30 percent. When will trading begin? The official schedule will follow the IPO process and the next IDX announcement.

If the final price lands at the top end, gross fundraising could approach Rp66.35 billion. That is the first figure the market will be watching closely.